Arctic Bioscience announces full year 2021 results
Highlights · Successful private placement and IPO raising NOK 300 million in growth capital on Euronext Growth · Phase IIb clinical study on HRO350 in mild-to-moderate psoriasis remains largely on track and on budget with site feasibility completed and sufficient number of patients secured · Announced collaboration to develop new drug candidate for brain development in extremely premature infants with Smerud Medical Research International (Smerud) · Awarded NOK 4.85 million grant from The Research Council of Norway to elucidate the Mechanism of Action (MOA) in HRO350 ·